ERBB2 and breast carcinoma: Acquired resistance to endocrine therapy is a major clinical challenge in the treatment of luminal A [estrogen receptor (ER)+ and/or progesterone receptor (PR)+, human epidermal growth factor receptor 2 (ERBB2/HER2)-, and low Ki-67] breast cancer.